Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.

@article{Diras2014TrastuzumabEI,
  title={Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.},
  author={V{\'e}ronique Di{\'e}ras and Nadia Harbeck and George Thomas Budd and Joel K. Greenson and Alice E Guardino and Meghna K Samant and Nataliya Chernyukhin and Melanie C. Smitt and Ian Krop},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 25},
  pages={
          2750-7
        }
}
PURPOSE The antibody-drug conjugate trastuzumab emtansine (T-DM1) combines the cytotoxic activity of DM1 with the human epidermal growth factor receptor 2 (HER2) -targeted, antitumor properties of trastuzumab. T-DM1 has shown activity in phase I and II single-arm studies in patients with pretreated HER2-positive metastatic breast cancer (MBC) and has demonstrated superior efficacy and improved tolerability versus standard MBC treatments in randomized phase II and III studies. This analysis… CONTINUE READING
Highly Cited
This paper has 32 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity.

Molecular cancer therapeutics • 2016
View 15 Excerpts
Method Support
Highly Influenced

Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology • 2015
View 4 Excerpts
Highly Influenced